GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

Esposito K, Mosca C, Brancario C, Chiodini P, Ceriello A, Giugliano D

Current medical research and opinion13 Jun 2011Cited by 40 (Europe PMC)

PMID21663496DOI10.1185/03007995.2011.590127PepBankPUB-21663496

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In people with type 2 diabetes, 47% of participants treated with liraglutide reached an HbA1c below 7%.
In plain wordsIn people with type 2 diabetes, 47% of those given liraglutide reached an HbA1c below 7%.
Peptide
Liraglutide
Outcome
Not applicableProportion reaching HbA1c below 7%
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Proportion reaching HbA1c <7%
47%
liraglutide
Source sentences
Summary
the proportion of participants achieving the HbA(1c) goal <7% was 46% for exenatide, 47% for liraglutide
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted an electronic search for randomized controlled trials (RCTs) involving GLP-1 agonists through September 2010.
Summary · context
RCTs were included if they lasted at least 12 weeks, included 30 patients or more, and reported the proportion of patients reaching the HbA(1c) target of <7%.
Report a problemFND-2166349602
02HumanSystematic reviewEfficacy outcome
In people with type 2 diabetes, liraglutide reduced HbA1c more than comparator drugs.
In plain wordsIn people with type 2 diabetes, liraglutide lowered HbA1c more than the comparator drugs.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction versus comparator drugs
Study
n: not reported in source
Comparator
Comparator drugs
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Moreover, the reduction of the HbA(1c) level and the rate of HbA(1c) goal attainment were higher for both exenatide LAR and liraglutide, as compared to comparator drugs.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted an electronic search for randomized controlled trials (RCTs) involving GLP-1 agonists through September 2010.
Summary · context
RCTs were included if they lasted at least 12 weeks, included 30 patients or more, and reported the proportion of patients reaching the HbA(1c) target of <7%.
Report a problemFND-2166349603
03HumanSystematic reviewEfficacy outcome
In people with type 2 diabetes, the rate of HbA1c goal attainment was higher with liraglutide than with comparator drugs.
In plain wordsIn people with type 2 diabetes, more people reached the HbA1c goal with liraglutide than with the comparator drugs.
Peptide
Liraglutide
Outcome
IncreaseHbA1c goal attainment versus comparator drugs
Study
n: not reported in source
Comparator
Comparator drugs
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Moreover, the reduction of the HbA(1c) level and the rate of HbA(1c) goal attainment were higher for both exenatide LAR and liraglutide, as compared to comparator drugs.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted an electronic search for randomized controlled trials (RCTs) involving GLP-1 agonists through September 2010.
Summary · context
RCTs were included if they lasted at least 12 weeks, included 30 patients or more, and reported the proportion of patients reaching the HbA(1c) target of <7%.
Report a problemFND-2166349604
04HumanSystematic reviewSafety outcome
In people with type 2 diabetes, hypoglycemia was more frequent with liraglutide than with placebo, and this was associated with concomitant sulfonylurea use.
In plain wordsIn people with type 2 diabetes, low blood sugar was more common with liraglutide than placebo, linked to use of a sulfonylurea.
Peptide
Liraglutide
Outcome
IncreaseHypoglycemia versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Higher rates of hypoglycemia with exenatide b.i.d. and liraglutide compared to placebo were associated with the concomitant use of a sulfonylurea.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted an electronic search for randomized controlled trials (RCTs) involving GLP-1 agonists through September 2010.
Summary · context
RCTs were included if they lasted at least 12 weeks, included 30 patients or more, and reported the proportion of patients reaching the HbA(1c) target of <7%.
Report a problemFND-2166349605
05HumanSystematic reviewEfficacy outcome
In people with type 2 diabetes, liraglutide was associated with weight loss compared with placebo or other antidiabetic drugs.
In plain wordsIn people with type 2 diabetes, liraglutide was linked to weight loss compared with placebo or other diabetes drugs.
Peptide
Liraglutide
Outcome
DecreaseWeight loss versus placebo or other antidiabetic drugs
Study
n: not reported in source
Comparator
Placebo or other antidiabetic drugs
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Exenatide b.i.d. and liraglutide were associated with weight loss compared to placebo or other antidiabetic drugs.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted an electronic search for randomized controlled trials (RCTs) involving GLP-1 agonists through September 2010.
Summary · context
RCTs were included if they lasted at least 12 weeks, included 30 patients or more, and reported the proportion of patients reaching the HbA(1c) target of <7%.
Report a problemFND-2166349606

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with type 2 diabetes, pooled GLP-1 agonists (exenatide and liraglutide) reduced HbA1c more than placebo.
In plain wordsIn people with type 2 diabetes, GLP-1 drugs as a group lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction versus placebo (pooled GLP-1 agonists)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
GLP-1 agonists showed a statistically significant reduction in HbA(1c) compared to placebo
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted an electronic search for randomized controlled trials (RCTs) involving GLP-1 agonists through September 2010.
Summary · context
RCTs were included if they lasted at least 12 weeks, included 30 patients or more, and reported the proportion of patients reaching the HbA(1c) target of <7%.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2166349601
07HumanNot a test of Liraglutide aloneSystematic reviewOther
In the pooled GLP-1 agonist trials, baseline HbA1c was the best predictor of reaching the HbA1c target.
In plain wordsAcross GLP-1 drug trials in type 2 diabetes, the starting HbA1c best predicted who reached the target.
Peptide
Liraglutide
Outcome
Not applicableBaseline HbA1c as predictor of target attainment (pooled GLP-1 agonists)
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Baseline HbA(1c) was the best predictor for achievement of A1c target (overall weighted R(2) value = 0.513, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted an electronic search for randomized controlled trials (RCTs) involving GLP-1 agonists through September 2010.
Summary · context
RCTs were included if they lasted at least 12 weeks, included 30 patients or more, and reported the proportion of patients reaching the HbA(1c) target of <7%.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2166349607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.